Her-2阴性乳腺癌中激素受体、Ki-67、P53的表达与蒽环类新辅助化疗疗效的关系  

Hormone receptors 、Ki- 67、P53 expression in Her-2 negative breast cancer and its relationship with neoadjuvant anthracycline- based chemotherapy in breast cancer

作　　者：徐玲玉[1] 江勇[1] 杨澜[1] 

机构地区：[1]苏州大学附属第三医院,常州213000

出　　处：《河南外科学杂志》2014年第4期5-7,共3页Henan Journal of Surgery

摘　　要：目的探讨Her-2阴性乳腺癌中激素受体、Ki-67、P53的表达与蒽环类新辅助化疗疗效的关系。方法应用免疫组化法测定78例Her-2阴性乳腺浸润性导管癌蒽环类新辅助化疗前ER、PR、Ki-67、P53的表达。四个周期CEF或AC方案化疗后进行临床及病理疗效评价。结果激素受体双阳或单阳组与激素受体双阴组相比,临床总有效率及术后病理有效率有显著性差异(P<0.05);Ki-67阳性组与Ki-67阴性组相比,临床总有效率无显著性差异(P>0.05),术后病理有效率有显著性差异(P<0.05);P53阳性组与P53阴性组相比,临床总有效率及术后病理有效率均未见显著性差异(P>10.05)。结论激素受体阴性、Ki-67阳性对Her-2阴性乳腺癌患者蒽环类新辅助化疗的敏感性较高,激素受体状态、Ki-67可能成为判断Her-2阴性乳腺癌蒽环类新辅助化疗疗效的重要指标。Objective To investigate hormone receptors 、Ki-67、P53 Expression in Her-2 negative breast cancer and its relationship with neoadjuvant anthracycline- based chemotherapy in breast cancer. Methods The expressions of hormone receptors 、Ki- 67、P53 in 78 cases of Her- 2 negative breast cancer patients were detected by immunohistochemistry method before neoadjuvant chemotherapy. We used clinical and pathology to evaluate thetherapeutic effectiveness after 4 cycles of neoadjuvant anthracycline- based chemotherapy. Results Compared the effective rates of the ER or PR Positive and ER 、PR absent groups,there was statistical significance by clinical and pathology effectiveness( P <0.05); Compared the effective rates of the Ki-67 postive and Ki-67 negative groups,there was no statistical significance by clinical effectiveness( P > 0. 05),but there was statistical significance by pathology effectiveness( P < 0. 05); Compared the effective rates of the p53 postive and P53 negative groups,there was no statistical significance by clinical and pathology effectiveness( P > 0. 05). Conclusion Her- 2negativebreast cancer with ER and PR absent 、Ki- 67 postive maybe more sensitive to neoadjuvant anthracycline- based chemotherapy. The expression status of Hormone receptors 、Ki- 67 can well predict the efficiency of neoadjuvant anthracycline- based chemotherapy in Her- 2negative breast cancer.

关 键 词：激素受体 KI-67 P53 Her-2阴性乳腺癌蒽环类新辅助化疗疗效 

分 类 号：R737.9[医药卫生—肿瘤]